Insider Buying: Immuneering (NASDAQ:IMRX) Insider Purchases 2,298 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the firm's stock in a transaction that occurred on Thursday, January 15th. The shares were bought at an average price of $4.57 per share, with a total value of $10,501.86. Following the acquisition, the insider directly owned 376,496 shares of the company's stock, valued at $1,720,586.72. The trade was a 0.61% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.Immuneering Stock PerformanceNASDAQ:IMRX traded down $0.06 during trading hours on Friday, reaching $4.58. The stock had a trading volume of 1,571,491 shares, compared to its average volume of 4,332,983. The stock has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $5.77. Immuneering Corporation has a 12-month low of $1.10 and a 12-month high of $10.08. The stock has a market cap of $295.73 million, a P/E ratio of -2.57 and a beta of 0.48. Immuneering (NASDAQ:IMRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.01). On average, equities analysts expect that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year. Hedge Funds Weigh In On ImmuneeringA number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Immuneering during the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Future Financial Wealth Managment LLC bought a new position in Immuneering during the 3rd quarter valued at approximately $35,000. Kingsview Wealth Management LLC purchased a new position in Immuneering during the second quarter valued at $47,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Immuneering in the third quarter worth $70,000. 67.65% of the stock is owned by institutional investors. Analyst Upgrades and DowngradesIMRX has been the topic of several research reports. Leerink Partnrs upgraded shares of Immuneering to a "strong-buy" rating in a research report on Friday, October 31st. Mizuho set a $12.00 target price on Immuneering in a research note on Wednesday, October 29th. HC Wainwright restated a "buy" rating and set a $11.00 price target on shares of Immuneering in a research report on Tuesday, September 30th. Wall Street Zen cut Immuneering from a "hold" rating to a "sell" rating in a report on Saturday, December 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Immuneering in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $16.50.Check Out Our Latest Research Report on IMRXAbout Immuneering (Get Free Report)Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need. The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.Featured StoriesFive stocks we like better than ImmuneeringNEW LAW: Congress Approves Setup For Digital Dollar?A month before the crashHow a Family Trust May Be Able To Help Preserve Your WealthWhy Trump and Musk suddenly care about Fort KnoxIf You Keep Cash In A U.S. Bank Account… Read This NOWThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Immuneering Right Now?Before you consider Immuneering, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.While Immuneering currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here